Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01167 JACOBIO-B > Company Profile
01167 JACOBIO-B
6.310
+1.180+23.00%
Symbol
01167
Company Name
JACOBIO-B
ISIN
KYG4987A1094
Listing Date
12/21/2020
Establishment Date
06/01/2018
Registration
Cayman Islands
Chairman
Yinxiang Wang
Secretary
Qing\zhongminghui Xue
Audit Institution
PricewaterhouseCoopers
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Walkers Corporate Limited, 190 Elgin Avenue, George Town,Grand Cayman KY1-9008, Cayman Islands
Head Office and Principal Place of Business
40 / F, Dah Sing Financial Centre, 248 Queen's Road East, Wanchai, Hong Kong
Fiscal Year Ends
12-31
Employees
285
Market
Hong Kong motherboard
Phone
(010)56315466
Fax
(010)56315314
Email
IR@jacobiopharma.com
Business
Jiakos Pharmaceutical Group Co., Ltd. is a Chinese investment holding company mainly engaged in clinical drug research and development. The company is mainly responsible for the independent discovery and development of innovative tumor therapy. The company's main drug development projects include JAB-3068 and allosteric SHP2 inhibitors in the clinical phase of JAB-3312. The company mainly does business in the domestic market.
Profile
Jiakos Pharmaceutical Group Co., Ltd. is committed to providing breakthrough treatment solutions for patients, and the company's vision is to work with partners to become a globally recognized leader in drug research and development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platform has allosteric inhibitors for the development of protein phosphatase, KRAS and other transcription factors. Garkos has received investment from several biotechnology investment institutions, including QiMing Venture Partners, Lilly Asia Fund, Hillhouse and Taiwan Yusheng.
Company Overview
Jiakos Pharmaceutical Group Co., Ltd. is committed to providing breakthrough treatment solutions for patients, and the company's vision is to work with partners to become a globally recognized leader in drug research and development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platform has allosteric inhibitors for the development of protein phosphatase, KRAS and other transcription factors. Garkos has received investment from several biotechnology investment institutions, including QiMing Venture Partners, Lilly Asia Fund, Hillhouse and Taiwan Yusheng.
CEO: Yinxiang Wang
Market: Hong Kong motherboard
Listing Date: 12/21/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist